Literature DB >> 11251337

Antiphospholipid syndrome: state of the art with emphasis on laboratory evaluation.

M Greaves1.   

Abstract

Antiphospholipid antibodies (aPLs) are associated with arterial and venous thrombosis, recurrent pregnancy loss and thrombocytopenia. Although aPLs have not yet been conclusively shown to be causal in thrombosis and miscarriage, they are useful laboratory markers for the antiphospholipid syndrome (APS). The syndrome can complicate another autoimmune disease, most commonly systemic lupus erythematosus, but more often occurs alone -- primary APS. Identification of the syndrome is clinically important because of the risk of recurrent thrombosis and the need for antithrombotic therapy in many cases. Diagnosis and treatment of APS represent significant challenges, however, owing to the protean clinical manifestations and associations, limitations of currently available laboratory tests for aPLs, and the lack of clear evidence-based guidance on optimal management. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11251337     DOI: 10.1159/000054159

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  4 in total

Review 1.  Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease.

Authors:  M Ángeles Martínez-Zamora; Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 2.  Recent advances in the diagnosis of antiphospholipid syndrome.

Authors:  Hyun-Sook Chi
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Lupus anticoagulants in two children--bleeding due to nonphospholipid-dependent antiprothrombin antibodies.

Authors:  Karin Knobe; Ulf Tedgård; Torben Ek; Per-Erik Sandström; Andreas Hillarp
Journal:  Eur J Pediatr       Date:  2012-04-19       Impact factor: 3.183

4.  Upregulated serum granulysin levels in women with antiphospholipid antibody-associated recurrent miscarriage are downregulated by heparin treatment.

Authors:  Tomoko Ichikawa; Yasuyuki Negishi; Sayuri Kasano; Ryoko Yokote; Mirei Yonezawa; Nozomi Ouchi; Yoshimitsu Kuwabara; Shunji Suzuki; Toshiyuki Takeshita
Journal:  Reprod Med Biol       Date:  2022-04-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.